Cinzia Azzoni

Dr. Cinzia Azzoni


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2011 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
CACinzia Azzoni
Cinzia Azzoni
LBLorena Bottarelli
Lorena Bottarelli
SCStefano Cecchini
Stefano Cecchini
CLCostanza Lagrasta
Costanza Lagrasta
SPSilvia Pizzi
Silvia Pizzi
CBCesare Bordi
Cesare Bordi

19 February 2011 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
CACinzia Azzoni
Cinzia Azzoni
LBLorena Bottarelli
Lorena Bottarelli
SCStefano Cecchini
Stefano Cecchini
ESEnrico Maria Silini
Enrico Maria Silini
CBCesare Bordi
Cesare Bordi
LSLeopoldo Sarli
Leopoldo Sarli

23 May 2025 in Genes
Verified
Journal Article
Open access
PDF file
BMBarbara Moschella
Barbara Moschella
SBSabrina Busciglio
Sabrina Busciglio
EAEnrico Ambrosini
Enrico Ambrosini
SCSofia Cesarini
Sofia Cesarini
LCLuca Caramanna
Luca Caramanna
Antonio PercesepeAntonio Percesepe
Antonio Percesepe
Darier′s disease (DD) is a rare, autosomal dominant genodermatosis caused by pathogenic variants in the ATP2A2 gene, which encodes the SERCA2 protein, an endoplasmic reticulum ATPase Ca2+ transporter. These mutations impair the intracellular calcium homeostasis leading to increased protein misfolding, endoplasmic reticulum (ER) stress response, and the activation of the unfolded protein response (UPR), culminating in keratinocyte apoptosis and anomalies in interfollicular epidermal stratification. Clinically, the disease is characterized by the presence of skin lesions with hyperkeratotic papules and an increased susceptibility to inflammatory reactions, bacterial and viral infections. The histological hallmarks include acantholysis, dyskeratosis, and increased apoptotic keratinocytes, referred to as “corp ronds”. The SERCA2b isoform is expressed not only in the epidermis but it is present ubiquitously in all tissues, suggesting that its alteration may have multi-organ effects. The review aims to provide a broad overview of the pathology, from intracellular dysfunction to the clinical manifestations, elucidating the molecular effects of SERCA2 variants found in DD patients and exploring the potential cell signaling pathways that may contribute to disease progression. Beginning with an examination of the cellular alterations, our work then shifts to exploring their impact in an organ-specific context, providing insights into new potential therapeutic strategies tailored to clinical manifestations.

1 October 2013
Verified
Journal Article
Closed access
FNFrancesca Negri
Francesca Negri
CACinzia Azzoni
Cinzia Azzoni
LBLorena Ospedaliera Universitaria Bottarelli
Lorena Ospedaliera Universitaria Bottarelli
NCNicoletta Campanini
Nicoletta Campanini
AMAlessandra Mandolesi
Alessandra Mandolesi
AAAndrea Ardizzoni
Andrea Ardizzoni

11 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SBSabrina Busciglio
Sabrina Busciglio
ICIlenia Rita Cannizzaro
Ilenia Rita Cannizzaro
ALAnita Luberto
Anita Luberto
ATAntonietta Taiani
Antonietta Taiani
BMBarbara Moschella
Barbara Moschella
Antonio PercesepeAntonio Percesepe
Antonio Percesepe
Neurofibromatosis type 1 (NF1) predisposes to a spectrum of peripheral nerve sheath tumors, ranging from benign plexiform neurofibromas (PN) to atypical neurofibromatous neoplasms of uncertain biological potential (ANNUBP) and malignant peripheral nerve sheath tumors (MPNST). Tumorigenesis follows a multistep molecular cascade initiated by biallelic NF1 inactivation, followed by CDKN2A loss and disruption of the Polycomb Repressive Complex 2 (PRC2). These events guide chromatin remodeling, widespread epigenetic dysregulation, and activation of oncogenic pathways such as RAS/MAPK and PI3K/AKT. Here, we integrate genomic, transcriptomic, and epigenomic studies to delineate the molecular trajectories underlying tumor progression and to define promising biomarkers for the early detection of malignant transformation. Emerging liquid biopsy approaches, based on circulating tumor DNA (ctDNA) analyses, reveal distinctive copy number variations (CNVs) and methylation patterns that mirror tissue-derived profiles, enabling the detection of malignant transformation. Together, these findings support a model in which cumulative genetic and epigenetic alterations drive the PN–ANNUBP–MPNST continuum. They also underscore the value of multi-omics and liquid biopsy-based strategies to improve early diagnosis, patient risk stratification, and personalized management of NF1-associated tumors, thereby advancing precision medicine in this complex disease spectrum.

1 February 2014 in Pathology - Research and Practice
Verified
Journal Article
Closed access
CACinzia Azzoni
Cinzia Azzoni
LBLorena Bottarelli
Lorena Bottarelli
SCStefano Cecchini
Stefano Cecchini
AZAntonio Ziccarelli
Antonio Ziccarelli
NCNicoletta Campanini
Nicoletta Campanini
ESEnrico Maria Silini
Enrico Maria Silini